| Literature DB >> 31528339 |
Diana Luise1, Micol Bertocchi2, Vincenzo Motta1, Chiara Salvarani1, Paolo Bosi1, Andrea Luppi3, Flaminia Fanelli4, Maurizio Mazzoni5, Ivonne Archetti3, Giuseppe Maiorano2, Bea K K Nielsen6, Paolo Trevisi1.
Abstract
BACKGROUND: Probiosis is considered a potential strategy to reduce antibiotics use and prevent post-weaning diarrhea (PWD). This study investigated the effect of Bacillus amyloliquefaciens DSM25840 or Bacillus subtilis DSM25841 supplementation on growth, health, immunity, intestinal functionality and microbial profile of post-weaning pigs after enterotoxigenic E. coli (ETEC) F4 challenge.Entities:
Keywords: Bacillus amyloliquefaciens; Bacillus subtilis; Diarrhea; ETEC; Gut microbiota; Post-weaning; Transcriptomics
Year: 2019 PMID: 31528339 PMCID: PMC6740008 DOI: 10.1186/s40104-019-0380-3
Source DB: PubMed Journal: J Anim Sci Biotechnol ISSN: 1674-9782
Ingredient and calculated composition of the basal diet (g/kg as fed basis)
| Items | Content |
|---|---|
| Ingredients, % | |
| Corn | 27.00 |
| Barley | 25.10 |
| Biscuit by-product | 20.00 |
| Rice protein concentrate | 4.20 |
| Milk whey | 4.00 |
| Wheat middlings | 4.00 |
| Soybean meal, 50% CP | 3.00 |
| Wheat gluten | 2.50 |
| Soy oil | 3.50 |
| Brewer’s yeast | 2.00 |
| Potato, protein concentrate | 1.50 |
| Dicalcium phosphate | 1.00 |
| Carrob pulp | 1.00 |
| Miner-vitamin premix | 0.50 |
| Calcium carbonate | 0.50 |
| Salt | 0.20 |
| Calculated chemical composition | |
| Crude protein, % | 16.50 |
| Crude fat, % | 5.80 |
| Crude fibre, % | 3.12 |
| Ash, % | 4.22 |
| Ca, % | 0.60 |
| P, % | 0.50 |
| NaCl, % | 0.38 |
| Cu, mg | 150 |
| Zn, mg | 135 |
| Lysine,% | 1.20 |
| Met + Cys, % | 0.70 |
| ME, kcal/kg | 3144 |
ME Metabolic energy, the values were estimated by the EvaPig® software [22] using information from the INRA-AFZ tables of feedstuff composition (INRA-AFZ, 2004)
Effect of dietary supplementation of Bacillus amyloliquefaciens DSM25840 and Bacillus subtilis DSM25841 on fecal score and days of diarrhea of weaned pigs challenged with Escherichia coli F4ac
| Items | Treatmentsa | SEM | ||||||
|---|---|---|---|---|---|---|---|---|
| BAA | BAS | AB | CO | BAA vs. CO | BAS vs. CO | AB vs. CO | ||
| Fecal score | ||||||||
| Day 6b | 3.75 | 3.72 | 1.97 | 3.63 | 0.27 | 0.45 | 0.54 | < 0.001 |
| Day 8c | 3.66 | 3.44 | 1.9 | 3.38 | 0.28 | 0.28 | 0.68 | < 0.001 |
| Day 14d | 3 | 2.4 | 1.78 | 3.4 | 0.38 | 0.4 | 0.06 | 0.01 |
| Day 21d | 3.15 | 2.6 | 1.89 | 3.4 | 0.34 | 0.56 | 0.11 | 0.01 |
aBAA B. amyloliquefaciens DSM25840, BAS B. subtilis DSM25841, AB Antibiotic, CO Control
bNumber of animals was 16 for BAA, BAS and CO groups; 15 for AB group
cNumber of animals was: 14 for BAA; 15 for BAS, AB and CO.
dNumber of animals was 6 for BAA; 9 for BAS; 10 for AB; 6 for CO
Effect of dietary supplementation of Bacillus amyloliquefaciens DSM25840 and Bacillus subtilis DSM25841 on growth performance of weaned pigs challenged with Escherichia coli F4ac
| Items | Treatmentsa | SEM | ||||||
|---|---|---|---|---|---|---|---|---|
| BAA | BAS | AB | CO | BAA vs. CO | BAS vs. CO | AB vs. CO | ||
| Body weight, g | ||||||||
| Initialb | 7779 | 7789 | 7869 | 7619 | 266 | 0.60 | 0.60 | 0.49 |
| Day 7c | 7638 | 7581 | 8208 | 7356 | 308 | 0.64 | 0.60 | 0.02 |
| Day 14d | 8912 | 8279 | 9201 | 8370 | 350 | 0.33 | 0.92 | 0.05 |
| Final (day 21) | 10855 | 10036 | 11319 | 10102 | 549 | 0.28 | 0.94 | 0.03 |
| Average daily live weight gain, g/d | ||||||||
| Day 0 - day 7c | −27.6 | −41.6 | 48.5 | −62.3 | 28.7 | 0.61 | 0.99 | < 0.001 |
| Day 7 - day 14d | 130 | 108 | 138 | 111 | 29.8 | 0.32 | 0.65 | 0.30 |
| Day 14 - day 21d | 278 | 251 | 303 | 248 | 35.4 | 0.46 | 0.75 | 0.12 |
| Post-challenge (day 8 - day 21)d | 204 | 179 | 220 | 179 | 29.1 | 0.27 | 0.63 | 0.09 |
| Total (day 0 - day 21)d | 129 | 99 | 156 | 109 | 28.3 | 0.51 | 0.60 | 0.10 |
| Average daily feed intake, g/d | ||||||||
| Day 0 - day 7c | 162 | 163 | 200 | 146 | 15.6 | 0.70 | 0.34 | < 0.001 |
| Day 7 - day 14d | 308 | 254 | 376 | 318 | 46.8 | 0.78 | 0.27 | 0.32 |
| Day 14 - day 21d | 535 | 532 | 612 | 519 | 47.1 | 0.75 | 0.71 | 0.07 |
| Post-challenge (day 8 - day 21) d | 421 | 393 | 494 | 418 | 44.6 | 0.99 | 0.65 | 0.11 |
| Total (day 0 - day 21) d | 329 | 318 | 396 | 330 | 33.3 | 0.82 | 0.72 | 0.06 |
| Gain to feed | ||||||||
| Day 0 - day 7c | −0.52 | −0.38 | 0.19 | −0.56 | 0.19 | 0.62 | 0.76 | < 0.001 |
| Day 7 - day 14 d | 0.38 | 0.37 | 0.23 | 0.34 | 0.11 | 0.54 | 0.61 | 0.57 |
| Day 14 - day 21 d | 0.51 | 0.46 | 0.49 | 0.47 | 0.03 | 0.35 | 0.93 | 0.39 |
| Post-challenge (day 8 - day 21) d | 0.46 | 0.44 | 0.44 | 0.42 | 0.03 | 0.06 | 0.11 | 0.22 |
| Total (day 0 - day 21) d | 0.36 | 0.28 | 0.38 | 0.30 | 0.05 | 0.22 | 0.74 | 0.20 |
aBAA B. amyloliquefaciens DSM25840, BAS B. subtilis DSM25841, AB Antibiotic, CO Control
bNumber of animals was 16 for BAA, BAS and CO groups; 15 for AB group
cNumber of animals was: 14 for BAA; 15 for BAS, AB and CO.
dNumber of animals was: 6 for BAA; 9 for BAS; 10 for AB; 6 for CO
Effect of dietary supplementation of Bacillus amyloliquefaciens DSM25840 and Bacillus subtilis DSM25841 on the blood plasma metabolites showing statistical significances in weaned piglets challenged with Escherichia coli F4ac
| Metabolite, μmol/L | Treatmentsa | SEM | ||||||
|---|---|---|---|---|---|---|---|---|
| BAA | BAS | AB | CO | BAA vs. CO | BAS vs. CO | AB vs. CO | ||
| Day 8b | ||||||||
| Arg | 107.0 | 117.1 | 105.2 | 145.3 | 16.8 | 0.02 | 0.11 | 0.02 |
| Gly | 657.3 | 597 | 785.7 | 893.7 | 72.3 | 0.08 | 0.02 | 0.64 |
| Lys | 191.5 | 225.7 | 188.3 | 246.3 | 19.3 | 0.03 | 0.03 | 0.02 |
| Orn | 58.0 | 65.4 | 63.8 | 82.9 | 11.0 | 0.04 | 0.19 | 0.14 |
| Pro | 228.5 | 216.5 | 242.5 | 292.6 | 23.6 | 0.14 | 0.07 | 0.31 |
| Ser | 111.1 | 101.7 | 116.4 | 133.1 | 6.8 | 0.22 | 0.05 | 0.44 |
| Thr | 91.1 | 123.5 | 78.1 | 180.4 | 28.0 | 0.1 | 0.41 | 0.05 |
| Tyr | 51.2 | 57.8 | 53.1 | 69.4 | 5.0 | 0.06 | 0.34 | 0.11 |
| Histamine | 153.4 | 73.1 | 81.5 | 73.4 | 12.5 | 0.07 | 0.85 | 0.98 |
| PC.aa.C30.0 | 1.2 | 1.1 | 1.4 | 1.4 | 0.1 | 0.27 | 0.05 | 0.93 |
| Day 21c | ||||||||
| Gly | 1058 | 927.8 | 910.1 | 791.2 | 55.8 | 0.04 | 0.39 | 0.5 |
| Gln | 551 | 482.6 | 502.3 | 454.7 | 25.8 | 0.05 | 0.82 | 0.46 |
| Ser | 154.7 | 138.9 | 143.7 | 113.6 | 9.9 | 0.07 | 0.31 | 0.18 |
| SDMA | 0.7 | 1.0 | 0.9 | 1.3 | 0.2 | 0.07 | 0.51 | 0.22 |
aBAA B. amyloliquefaciens DSM25840, BAS B. subtilis DSM25841, AB Antibiotic, CO Control
b Number of included animals was: 14 for BAA; 15 for BAS, AB and CO.
c Number of included animals was: 6 for BAA; 9 for BAS; 10 for AB; 6 for CO
Effect of dietary supplementation of Bacillus amyloliquefaciens DSM25840 and Bacillus subtilis DSM25841 on the blood serum IgA, IgG and IgM of weaned piglets challenged with Escherichia coli F4ac
| Igs | Treatmentsa | SEM | ||||||
|---|---|---|---|---|---|---|---|---|
| BAA | BAS | AB | CO | BAA vs. CO | BAS vs. CO | AB vs. CO | ||
| Day 6, mg/mLb | ||||||||
| IgA | 0.41 | 0.46 | 0.37 | 0.49 | 0.10 | 0.84 | 0.98 | 0.63 |
| IgG | 19.80 | 13.72 | 13.92 | 13.54 | 2.61 | 0.09 | 0.96 | 0.91 |
| IgM | 3.88 | 2.85 | 2.84 | 3.06 | 0.28 | 0.04 | 0.59 | 0.55 |
| Day 12, mg/mLc | ||||||||
| IgA | 0.72 | 0.46 | 0.42 | 0.54 | 0.09 | 0.51 | 0.85 | |
| IgG | 17.94 | 13.6 | 12.57 | 15.84 | 2.24 | 0.55 | 0.48 | 0.31 |
| IgM | 3.75 | 3.96 | 3.03 | 3.38 | 0.54 | 0.66 | 0.45 | 0.64 |
| Day 21, mg/mLd | ||||||||
| IgA | 0.72 | 0.96 | 0.65 | 0.68 | 0.08 | 0.92 | 0.04 | 0.98 |
| IgG | 10.57 | 11.58 | 11.88 | 12.14 | 1.35 | 0.45 | 0.71 | 0.89 |
| IgM | 2.86 | 3.25 | 2.75 | 2.82 | 0.32 | 0.93 | 0.34 | 0.88 |
aBAA B. amyloliquefaciens DSM25840, BAS B. subtilis DSM25841, AB Antibiotic, CO Control
bNumber of animals was 16 for BAA, BAS and CO groups; 15 for AB group
cNumber of animals was: 14 for BAA; 15 for BAS, AB and CO.
dNumber of animals was: 6 for BAA; 9 for BAS; 10 for AB; 6 for CO
Effect of the dietary supplementations of Bacillus amyloliquefaciens DSM25840 and Bacillus subtilis DSM25841 on abundance of microbial families of weaned piglet 14 days after the Escherichia coli F4ac challenge
| Family | Treatmentsa | SEM | FDR, | ||||
|---|---|---|---|---|---|---|---|
| BAA | BAS | AB | CO | ||||
| Jejunum | |||||||
| Pasteurellaceae | 1.53 | 1.07 | 0.01 | 13.62 | 0.12 | 0.024 | 1.189 |
| Succinivibrionaceae | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.115 | 2.827 |
| Moraxellaceae | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.135 | 2.199 |
| Cecum | |||||||
| Enterobacteriaceae | 0.14 | 0.38 | 0.01 | 1.05 | 0.03 | 0.001 | 0.058 |
| Ruminococcaceae | 8.20 | 21.82 | 20.96 | 24.43 | 0.09 | 0.011 | 0.273 |
| Peptostreptococcaceae | 0.02 | 0.05 | 0.10 | 0.25 | 0.01 | 0.013 | 0.213 |
aBAA B. amyloliquefaciens DSM25840, BAS B. subtilis DSM25841, AB Antibiotic, CO Control. Data are reported as mean of relative abundance %
Effect of the dietary supplementations of Bacillus amyloliquefaciens DSM25840 on the transcriptomic profile of jejunum mucosa of weaned piglet 14 days after the Escherichia coli F4ac challenge
| Name of the enriched gene set | Size, No. of genes | NES | FDR, | |
|---|---|---|---|---|
| Gene sets enriched in BAA respect to COa | ||||
| STRUCTURAL_CONSTITUENT_OF_RIBOSOME | 56 | 2.69 | < 0.001 | < 0.001 |
| MITOCHONDRIAL_MEMBRANE_PART | 40 | 2.22 | < 0.001 | < 0.001 |
| MITOCHONDRIAL_RESPIRATORY_CHAIN | 19 | 2.11 | < 0.001 | 0.01 |
| RIBOSOME | 25 | 2.08 | < 0.001 | 0.01 |
| MITOCHONDRIAL_INNER_MEMBRANE | 51 | 2.02 | < 0.001 | 0.02 |
| Gene sets enriched in CO respect to BAAa | ||||
| EXONUCLEASE_ACTIVITY | 15 | −2.20 | < 0.001 | < 0.001 |
| EXTRACELLULAR_MATRIX_PART | 42 | −2.20 | < 0.001 | < 0.001 |
| HELICASE_ACTIVITY | 43 | −2.20 | < 0.001 | < 0.001 |
| PROTEINACEOUS_EXTRACELLULAR_MATRIX | 74 | −2.10 | < 0.001 | < 0.001 |
| EXTRACELLULAR_MATRIX | 75 | −2.10 | < 0.001 | < 0.001 |
| DNA_HELICASE_ACTIVITY | 23 | − 2.10 | < 0.001 | < 0.001 |
| MEIOTIC_CELL_CYCLE | 29 | − 2.00 | < 0.001 | < 0.001 |
| LIGASE_ACTIVITY | 82 | −2.00 | < 0.001 | < 0.001 |
| CELL_CYCLE_PHASE | 136 | −2.00 | < 0.001 | 0.01 |
| DNA_REPAIR | 105 | −2.00 | < 0.001 | 0.01 |
TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE _KINASE _ACTIVITY | 39 | −2.00 | < 0.001 | 0.01 |
| CHROMATIN_BINDING | 26 | −2.00 | < 0.001 | 0.01 |
| CELL_CYCLE_PROCESS | 154 | −2.00 | < 0.001 | 0.01 |
| DNA_DEPENDENT_DNA_REPLICATION | 43 | −2.00 | < 0.001 | 0.01 |
| M_PHASE | 95 | −2.00 | < 0.001 | < 0.001 |
| COLLAGEN | 17 | −2.00 | 0.002 | < 0.001 |
| BASEMENT_MEMBRANE | 28 | −2.00 | < 0.001 | 0.01 |
TRANSMEMBRANE_RECEPTOR_PROTEIN _KINASE_ACTIVITY | 47 | −2.00 | < 0.001 | 0.01 |
| RESPONSE_TO_DNA_DAMAGE_STIMULUS | 135 | −1.90 | < 0.001 | 0.01 |
| DNA_REPLICATION | 69 | −1.90 | < 0.001 | 0.01 |
aBAA B. amyloliquefaciens DSM25840, CO Control
Effect of the dietary supplementations of Bacillus subtilis DSM25841 on the transcriptomic profile of jejunum mucosa of weaned piglet 14 days after the Escherichia coli F4ac challenge
| Name of the enriched gene set | Size, No. of genes | NES | FDR, | |
|---|---|---|---|---|
| Gene sets enriched in BAS respect to COa | ||||
| RHODOPSIN_LIKE_RECEPTOR_ACTIVITY | 97 | 2.66 | < 0.001 | < 0.001 |
| MONOVALENT_INORGANIC_CATION_TRANSPORT | 72 | 2.49 | < 0.001 | < 0.001 |
| SODIUM_ION_TRANSPORT | 17 | 2.43 | < 0.001 | < 0.001 |
| CELL_CELL_SIGNALING | 309 | 2.4 | < 0.001 | < 0.001 |
| CATION_CHANNEL_ACTIVITY | 90 | 2.37 | < 0.001 | < 0.001 |
| SUBSTRATE_SPECIFIC_CHANNEL_ACTIVITY | 119 | 2.3 | < 0.001 | < 0.001 |
| ION_CHANNEL_ACTIVITY | 112 | 2.27 | < 0.001 | < 0.001 |
| G_PROTEIN_COUPLED_RECEPTOR_ACTIVITY | 140 | 2.25 | < 0.001 | < 0.001 |
| HORMONE_ACTIVITY | 35 | 2.2 | < 0.001 | 0.01 |
| RESPONSE_TO_BACTERIUM | 22 | 2.19 | < 0.001 | 0.01 |
| CYCLIC_NUCLEOTIDE_MEDIATED_SIGNALING | 81 | 2.17 | < 0.001 | 0.01 |
| PEPTIDE_RECEPTOR_ACTIVITY | 36 | 2.16 | < 0.001 | 0.01 |
| G_PROTEIN_SIGNALING_COUPLED_TO_CYCLIC_NUCLEOTIDE _SECOND_MESSENGER | 79 | 2.14 | < 0.001 | 0.01 |
| VOLTAGE_GATED_CATION_CHANNEL_ACTIVITY | 52 | 2.13 | < 0.001 | 0.01 |
| INORGANIC_ANION_TRANSPORT | 16 | 2.13 | 0.005 | 0.01 |
| GATED_CHANNEL_ACTIVITY | 95 | 2.12 | < 0.001 | 0.01 |
| POTASSIUM_ION_TRANSPORT | 45 | 2.11 | < 0.001 | 0.01 |
| VOLTAGE_GATED_POTASSIUM_CHANNEL_COMPLEX | 32 | 2.08 | < 0.001 | 0.01 |
| G_PROTEIN_SIGNALING_COUPLED_TO_CAMP_NUCLEOTIDE_SECOND_MESSENGER | 51 | 2.08 | < 0.001 | 0.01 |
| CATION_TRANSPORT | 119 | 2.07 | < 0.001 | 0.01 |
| Gene sets enriched in CO respect to BASa | ||||
| MICROTUBULE_ORGANIZING_CENTER | 47 | −2.2 | < 0.001 | < 0.001 |
| CENTROSOME | 39 | −2.2 | < 0.001 | < 0.001 |
| MRNA_METABOLIC_PROCESS | 55 | −2.1 | < 0.001 | < 0.001 |
| LIGASE_ACTIVITY_FORMING_CARBON_NITROGEN_BONDS | 56 | −2.1 | < 0.001 | < 0.001 |
| NUCLEOPLASM | 227 | −2.1 | < 0.001 | < 0.001 |
| ACID_AMINO_ACID_LIGASE_ACTIVITY | 46 | −2.1 | < 0.001 | < 0.001 |
| MICROTUBULE_CYTOSKELETON | 110 | − 2.1 | < 0.001 | < 0.001 |
| LIGASE_ACTIVITY | 82 | −2 | < 0.001 | < 0.001 |
| NUCLEOPLASM_PART | 170 | −2 | < 0.001 | < 0.001 |
| RNA_PROCESSING | 125 | −2 | < 0.001 | < 0.001 |
| DNA_DIRECTED_RNA_POLYMERASEII_HOLOENZYME | 51 | −2 | < 0.001 | < 0.001 |
| SMALL_CONJUGATING_PROTEIN_LIGASE_ACTIVITY | 40 | −2 | < 0.001 | < 0.001 |
| MITOSIS | 68 | −2 | < 0.001 | < 0.001 |
| M_PHASE_OF_MITOTIC_CELL_CYCLE | 71 | −2 | < 0.001 | < 0.001 |
| MRNA_PROCESSING_GO_0006397 | 47 | −2 | < 0.001 | < 0.001 |
| CHROMOSOMAL_PART | 73 | −2 | < 0.001 | < 0.001 |
| CHROMOSOME_ORGANIZATION_AND_BIOGENESIS | 97 | −2 | < 0.001 | < 0.001 |
| CHROMOSOME | 94 | −2 | < 0.001 | < 0.001 |
| NUCLEAR_LUMEN | 310 | −2 | < 0.001 | < 0.001 |
| CELL_CYCLE_PROCESS | 154 | −2 | < 0.001 | < 0.001 |
a BAS B. subtilis DSM25841, CO Control
Effect of the dietary supplementations of antibiotic on the transcriptomic profile of jejunum mucosa of weaned piglet 14 days after the Escherichia coli F4ac challenge
| Name of the enriched gene set | Size, No. of genes | NES | FDR, | |
|---|---|---|---|---|
| Gene sets enriched in AB respect to COa | ||||
| LYMPHOCYTE_ACTIVATION | 50 | 2.22 | < 0.001 | < 0.001 |
| LEUKOCYTE_ACTIVATION | 56 | 2.2 | < 0.001 | < 0.001 |
| IMMUNE_SYSTEM_PROCESS | 260 | 2.17 | < 0.001 | < 0.001 |
| IMMUNE_RESPONSE | 182 | 2.3 | < 0.001 | < 0.001 |
| CELLULAR_DEFENSE_RESPONSE | 36 | 2.23 | < 0.001 | < 0.001 |
| T_CELL_ACTIVATION | 38 | 2.02 | < 0.001 | < 0.001 |
| CELL_ACTIVATION | 61 | 2.05 | < 0.001 | < 0.001 |
| LYMPHOCYTE_DIFFERENTIATION | 23 | 2.02 | < 0.001 | < 0.001 |
| DEFENSE_RESPONSE | 183 | 1.96 | < 0.001 | 0.01 |
| B_CELL_ACTIVATION | 16 | 1.92 | < 0.001 | 0.01 |
| REGULATION_OF_IMMUNE_SYSTEM_PROCESS | 53 | 1.88 | < 0.001 | 0.02 |
| POSITIVE_REGULATION_OF_IMMUNE_SYSTEM_PROCESS | 42 | 1.87 | < 0.001 | 0.02 |
| HEMOPOIETIC_OR_LYMPHOID_ORGAN_DEVELOPMENT | 67 | 1.86 | < 0.001 | 0.02 |
| LEUKOCYTE_DIFFERENTIATION | 33 | 1.86 | < 0.001 | 0.02 |
| INTERLEUKIN_RECEPTOR_ACTIVITY | 17 | 1.84 | 0.003 | 0.03 |
| INTERLEUKIN_BINDING | 22 | 1.82 | 0.003 | 0.03 |
| T_CELL_DIFFERENTIATION | 15 | 1.82 | 0.005 | 0.03 |
| REGULATION_OF_LYMPHOCYTE_ACTIVATION | 30 | 1.82 | < 0.001 | 0.03 |
| IMMUNE_SYSTEM_DEVELOPMENT | 70 | 1.83 | < 0.001 | 0.03 |
| PROTEIN_KINASE_CASCADE | 227 | 1.81 | < 0.001 | 0.03 |
| Gene sets enriched in CO respect to ABa | ||||
| AMINE_TRANSMEMBRANE_TRANSPORTER_ACTIVITY | 32 | −2.2 | < 0.001 | 0.01 |
| L_AMINO_ACID_TRANSMEMBRANE_TRANSPORTER_ACTIVITY | 15 | −2 | < 0.001 | 0.05 |
| CARBOXYLIC_ACID_TRANSMEMBRANE_TRANSPORTER_ACTIVITY | 35 | −2 | < 0.001 | 0.05 |
aAB Antibiotic, CO Control
Fig. 1Numbers of commonly up-regulated (a) and down-regulated (b) gene sets (FDR < 0.25) among BAA, BAS and AB groups, compared with the CO group. 9 Gene sets of intersection AB|BAA|BAS were up-regulated: LYMPHOCYTE_ACTIVATION, LEUKOCYTE_ACTIVATION, T_CELL_ACTIVATION, LYMPHOCYTE_DIFFERENTIATION, B_CELL_ACTIVATION, T_CELL_DIFFERENTIATION, CELL_STRUCTURE_DISASSEMBLY_DURING_APOPTOSIS, DETECTION_OF_EXTERNAL_STIMULUS, DETECTION_OF_STIMULUS. 5 Gene sets of intersection AB|BAA|BAS: TRANSMEMBRANE_RECEPTOR_PROTEIN_KINASE_ACTIVITY, TRANSMEMBRANE_ RECEPTOR_PROTEIN_TYROSINE_KINASE_ACTIVITY, ENDOMEMBRANE_SYSTEM, CELL_MATRIX_ADHESION, CELL_SUBSTRATE_ADHESION
Fig. 2Effect of the dietary supplementations of Bacillus amyloliquefaciens DSM25840, Bacillus subtilis DSM25841 and antibiotic on jejunal villi and crypt mitotic index of weaned piglets 14 days after the ETEC F4ac challenge. BAS and AB had a higher mitotic index in the jejunal villi than CO (P = 0.01). BAA: B. amyloliquefaciens DSM25840; BAS: B. subtilis DSM25841; AB: Antibiotic; CO: Control